Myriad Genetics Inc (MYGN)
7.415
+0.02
(+0.20%)
USD |
NASDAQ |
Apr 22, 16:00
7.50
+0.08
(+1.15%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 677.06M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -60.00% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.8018 |
| Price to Book Value | 0.9658 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0565 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 78.76% |
Profile
Edit
| Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services. |
| URL | https://www.myriad.com |
| Investor Relations URL | https://investor.myriad.com/ |
| HQ State/Province | Utah |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | May. 07, 2025 (est.) |
| Last Earnings Release | Feb. 24, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
| Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services. |
| URL | https://www.myriad.com |
| Investor Relations URL | https://investor.myriad.com/ |
| HQ State/Province | Utah |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | May. 07, 2025 (est.) |
| Last Earnings Release | Feb. 24, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |